{
  "abstract": "As the use of GLP-1 agonists such as semaglutide and tirzepatide for weight loss becomes increasingly common in adults, and obesity continues to increase in children and adolescents, should these treatments be widely available for younger people? Katharine Lang reports",
  "authors": [
    {
      "affiliations": [
        "Bristol"
      ],
      "name": "Katharine Lang"
    }
  ],
  "title": "Weight loss drugs: What do we know about the effects of Ozempic on children?",
  "uid": "39d3a618-29bf-59d8-949f-fc4ff512d64d"
}